|
|
[Report]
RNAI - A MARKET INSIGHT REPORT
Published: 2008/01
|
|
 |
|
|
|
Table of Contents
I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
- 1.Introduction
- Introduction to RNAi
- RNAi- Nature' s Way of Silencing Gene
- Definition
- Summary
- History of RNAi
- Segmentation of RNAi
- Exhibit 1: Segmentation of Global RNAi Market by Application
(Research, Therapeutics, Drug Development and Other) and Tools/Products
(Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries
and Other)
- Exhibit 2: Segmentation by Application (Research, Therapeutics, Drug
Development & Other)
- Exhibit 3: Segmentation by Tools/Products (Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other)
- Facts About RNAi
- Relation between siRNA Length and siRNA Function
- Functional Significance of siRNA Length
- Is siRNA Length Influential of siRNA Function?
- The Use of RNAi in Mammalian System
- 2.Global Market Analysis
- Exhibit 4: RNAi (2005-2012) -Global Market Analysis (Current & Future)
in US$ Million (Graphical Representation Included)
- Analysis by Segmentation
- Application
- Exhibit 5: RNAi (2005-2012)-Global Market Analysis (Current & Future)
by Application for Research, Therapeutics, Drug Development and Other in
US$ Million (Graphical Representation Included)
- Exhibit 6: RNAi (2006, 2009 and 2012) -Percentage Breakdown of Global
Market Value by Application for Research, Therapeutics, Drug Development
and Other
- Tools/Products
- Exhibit 7: RNAi (2005-2012) - Global Market Analysis (Current &
Future) by Tools/ Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries, and Other in US$ Million (Graphical Representation Included)
- Exhibit 8: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Global Market Value by Tools/ Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other
- Application Analysis by Geographic Region
- Research
- Exhibit 9: RNAi in Research (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 10: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Asia-Pacific and, Rest of World
- Therapeutics
- Exhibit 11: RNAi in Therapeutics (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 12: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Asia-Pacific, and Rest of World
- Drug Development
- Exhibit 13: RNAi in Drug Development (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 14: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Asia-Pacific, and Rest of World
- Other
- Exhibit 15: RNAi in Other Application (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 16: RNAi in Other Application (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Asia-Pacific and Rest of World
- Tools/Products Analysis by Geographic Region
- Design/Software
- Exhibit 17: RNAi Design/Software Tools/Products (2005-2012) - Global
Market Analysis (Current & Future) by Geographic Region for United States,
Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 18: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Asia-Pacific and Rest of World
- Synthesis
- Exhibit 19: RNAi Synthesis Tools/Products (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 20: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Asia-Pacific and Rest of World
- Delivery
- Exhibit 21: RNAi Delivery Tools/Products (2005-2012) - Global Market
Analysis (Current and Future) by Geographic Region for United States,
Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 22: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Asia-Pacific, and Rest of World
- Monitoring/Optimizing
- Exhibit 23: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Global Market Analysis (Current & Future) by Geographic Region for United
States, Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 24: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Global Market Value by Geographic Region
for United States, Europe, Asia-Pacific, and Rest of World
- Libraries
- Exhibit 25: RNAi Libraries (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 26: RNAi Libraries (2006, 2009 and 2012) - Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Asia-Pacific, and Rest of World
- Other
- Exhibit 27: RNAi - Other Tools/Products (2005-2012) - Global Market
Analysis (Current & Future) by Geographic Region for United States,
Europe, Asia-Pacific, and Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 28: RNAi - Other Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value by Geographic Region for
United States, Europe, Asia-Pacific, and Rest of World
- Exhibit 29: List of Major Global Companies
- 3. Regional Market Analysis
- United States
- Exhibit 30: RNAi (2005-2012) - United States Market Analysis (Current
& Future) in US$ Million (Graphical Representation Included)
- Major Companies in the US
- Allele Biotechnology and Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Ambion, Inc.
- Applied Biosystems Group
- Asuragen, Inc.
- Avalon Pharmaceuticals, Inc.
- B-Bridge International, Inc.
- Clontech Laboratories, Inc.
- Calando Pharmaceuticals, Inc.
- CombiMatrix Corporation
- CytRx Corporation
- RXi Pharmaceuticals Corporation
- Dharmacon, Inc.
- Galenea Corporation
- Imgenex Corporation
- Intradigm Corporation
- Intronn, Inc.
- Invitrogen Corporation
- InvivoGen
- Lentigen Corporation
- Merck & Co. , Inc.
- Mirus Bio Corporation
- Nastech Pharmaceutical Company, Inc.
- Nucleonics, Inc.
- Open Biosystems, Inc.
- Opko Health, Inc.
- Panomics, Inc.
- Promega Corporation
- SomaGenics, Inc.
- Sigma-Aldrich Corporation
- Targeted Genetics Corporation
- Analysis by Application
- Research
- Exhibit 31: RNAi in Research (2005-2012) - - United States Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Therapeutics
- Exhibit 32: RNAi in Therapeutics (2005-2012) - United States Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Drug Development
- Exhibit 33: RNAi in Drug Development (2005-2012) - United States
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Other
- Exhibit 34: RNAi in Other Application (2005-2012) - United States
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Tools/Products
- Design/Software
- Exhibit 35: RNAi Design/Software Tools/Products (2005-2012) - United
States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Synthesis
- Exhibit 36: RNAi Synthesis Tools/Products (2005-2012) - United States
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Delivery
- Exhibit 37: RNAi Delivery Tools/Products (2005-2012) - United States
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Monitoring/Optimizing
- Exhibit 38: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Libraries
- Exhibit 39: RNAi Libraries (2005-2012) - United States Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Other
- Exhibit 40: RNAi Other Tools/Products (2005-2012) - United States
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Europe
- Exhibit 41: RNAi (2005-2012) - European Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Major Companies in Europe
- Actigenics SA (France)
- Cenix Bioscience GmbH (Germany)
- deVGen NV (Belgium)
- Qiagen N V
- RNAx GmbH (Germany)
- Santaris Pharma A/S (Denmark)
- Silence Therapeutics plc (UK)
- Application Analysis by Geographic Region
- Research
- Exhibit 42: RNAi in Research (2005-2012) - European Market Analysis
(Current & Future) by Geographic Region for Germany, United Kingdom,
Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 43: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of European Market Value by Geographic Region for Germany,
United Kingdom, Belgium, France, and Rest of Europe
- Therapeutics
- Exhibit 44: RNAi in Therapeutics (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 45: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of European Market Value by Geographic Region for Germany,
United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Drug Development
- Exhibit 46: RNAi in Drug Development (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 47: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Other
- Exhibit 48: RNAi in Other Application (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 49: RNAi in Other Application (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Tools/Products Analysis by Geographic Region
- Design/Software
- Exhibit 50: RNAi Design/Software Tools/Products (2005-2012) -
European Market Analysis (Current & Future) by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe in US$
Million (Graphical Representation Included)
- Exhibit 51: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe
- Synthesis
- Exhibit 52: RNAi Synthesis Tools/Products (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for Germany,
United Kingdom, Belgium, France, and Rest of Europe in US$ Million
(Graphical Representation Included)
- Exhibit 53: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe(Graphical Representation Included)Delivery
- Exhibit 54: RNAi Delivery Tools/Products (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for Germany,
United Kingdom, Belgium, France, and Rest of Europe in US$ Million
(Graphical Representation Included)
- Exhibit 55: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe
- Monitoring/Optimizing
- Exhibit 56: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
European Market Analysis (Current & Future) by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe in US$
Million (Graphical Representation Included)
- Exhibit 57: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of European Market Value by Geographic
Region for Germany, UK, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Libraries
- Exhibit 58: RNAi Libraries (2005-2012) - European Market Analysis
(Current & Future) by Geographic Region for Germany, United Kingdom,
Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 59: RNAi Libraries (2006, 2009 and 2012) - Percentage
Breakdown of European Market Value by Geographic Region for Germany,
United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Other
- Exhibit 60: RNAi Other Tools/Products (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for Germany, United
Kingdom, Belgium, France, and Rest of Europe in US$ Million (Graphical Representation Included)
- Exhibit 61: RNAi Other Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value by Geographic Region for
Germany, United Kingdom, Belgium, France, and Rest of Europe (Graphical Representation Included)
- Asia-Pacific
- Exhibit 62: RNAi (2005-2012) - Asia-Pacific Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Major Companies in Asia-Pacific
- alphaGEN Co. , Ltd
- Antisense Therapeutics Limited (Australia)
- Benitec Ltd. (Australia)
- CytoPathfinder, Inc. (Japan)
- Application Analysis by Geographic Region
- Research
- Exhibit 63: RNAi in Research (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Australia, Japan, and
Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 64: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Asia-Pacific Market Value by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific
- Therapeutics
- Exhibit 65: RNAi in Therapeutics (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Australia, Japan, and
Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 66: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Asia-Pacific Market Value by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific
- Drug Development
- Exhibit 67: RNAi in Drug Development (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 68: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Other
- Exhibit 69: RNAi in Other Application (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 70: RNAi in Other Application (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Tools/Products Analysis by Geographic Region
- Design/Software
- Exhibit 71: RNAi Design/Software Tools/Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 72: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Synthesis
- Exhibit 73: RNAi Synthesis Tools/Products (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 74: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Delivery
- Exhibit 75: RNAi Delivery Tools/Products (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 76: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Monitoring/Optimizing
- Exhibit 77: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 78: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Asia-Pacific Market Value by Geographic
Region for Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Libraries
- Exhibit 79: RNAi Libraries (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) by Geographic Region for Australia, Japan, and Rest of
Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 80: RNAi Libraries (2006, 2009 and 2012) - Percentage
Breakdown of Asia-Pacific Market Value by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Other
- Exhibit 81: RNAi Other Tools/Products (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Geographic Region for Australia,
Japan, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
- Exhibit 82: RNAi Other Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for
Australia, Japan, and Rest of Asia-Pacific (Graphical Representation Included)
- Rest of World
- Exhibit 83: RNAi (2005-2012) - Rest of World Market Analysis (Current
& Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Research
- Exhibit 84: RNAi in Research (2005-2012) - Rest of World Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Therapeutics
- Exhibit 85: RNAi in Therapeutics (2005-2012) - Rest of World Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Drug Development
- Exhibit 86: RNAi in Drug Development (2005-2012) - Rest of World
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Other
- Exhibit 87: RNAi in Other Application (2005-2012) - Rest of World
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Tools/Products
- Design/Software
- Exhibit 88: RNAi Design/Software Tools/Products (2005-2012) - Rest
of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Synthesis
- Exhibit 89: RNAi Synthesis Tools/Products (2005-2012) - Rest of
World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Delivery
- Exhibit 90: RNAi Delivery Tools/Products (2005-2012) - Rest of World
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Monitoring/Optimizing
- Exhibit 91: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Libraries
- Exhibit 92: RNAi Libraries (2005-2012) - Rest of world Market
Analysis (Current & Future) in US$ Million (Graphical Representation Included)
- Other
- Exhibit 93: RNAi Other Tools/Products (2005-2012) - Rest of world
Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)
III. PRODUCT/TECHNOLOGY RESEARCH
- 1. Introduction
- Introduction to RNA
- Discovery of RNA interference
- Revelation of RNAi Mechanism
- System of RNAi
- Molecular Structure of RNA
- Synthesis of RNA
- Varieties of RNA and their Biological Roles
- Messenger RNA or mRNA in short
- Transfer RNA tRNA in short
- Ribosomal RNA or rRNA in short
- Non-coding RNA or "RNA genes"
- Double-stranded RNA or dsRNA in short
- Translation RNA
- Definition and Overview
- Vital Methods Involved in the Translation Mechanism
- Initiation Phase
- Elongation Phase
- Termination
- Eukaryotic Translation
- The Process of Initiation
- The Cap-Dependent Initiation
- The Cap-Independent Initiation
- Understanding the RNAissance
- RNAi Approaches in Production of Small RNAs for Host Gene Management
- RNAi Functions
- RNAi Growth Trends Global Markets
- Exhibit 94: Global RNAi Market: Geographic Regions (Rest of World,
Asia-Pacific, United States and Europe) Ranked by Projected CAGR for
2005 through 2012 (Graphical Representation Included)
- Discovery of RNA Interference
- Mechanism of Action
- Mechanism of RNA Interference
- Double-Stranded RNA Triggers RNAi
- Processing of dsRNA Triggers and Assembly with RISC
- RISC Assembly
- Effector/Silencing Step
- RNAi-Applications & Experiments
- RNAi in Plants
- History of Silencing Phenomena
- The Blue Rose A Result of Plant Gene Replacement
- Protein Complexes involved in the Development of Plants
- In Plant Biotechnology
- RNA interference and Antisense
- RNAi Knock-Down Mice: The New Technology for Post-Genomic Functional
Genetics
- The Development of RNAi Technology in Vivo
- RNAi Technology in Disease Models
- Introduction
- RNA interference in Therapeutic Applications
- Importance of RNAi
- RNAi Protects Against Viral Infections
- RNAi Maintains Genome Stability by Silencing the Mobile Elements
- Mechanisms Similar to RNAi Process Inhibit the Protein Synthesis and
Control the Development of Organisms
- RNAi like Mechanisms Suppress Transcription and Condense Chromatin
- RNAi May be the New Tool for Gene repression
- RNAi Might Prove Useful in Future Gene Therapy
- Applications of RNAi
- Therapeutics
- Development of RNAi based Therapies
- Non Therapeutics
- Other RNAi Applications
- RNA Interference Mode of Action
- RNA Polymerase Involved in PTGS has Two Different Kinds of Action
- New Method of Epigenetic Gene Silencing Involving RNA and Polycomb
Group Proteins
- Gene Silencing A Tool to Inactivate Gene of our Choice
- About Gene Silencing
- Brief History of Gene Silencing Processes
- Exhibit 95: A Comparative Analysis of Gene Silencing Techniques by
Strategy, Type of Agent, and Outcome
- Transcriptional and Post Transcriptional Gene Silencing
- Post-Transcriptional Gene Silencing and RNAi Mechanism
- Other Gene Silencing Methods through RNAi
- Schematic of a Typical siRNA Expression Vector
- Long Term Silencing of GFP with pSilencerTM 2 1U6 Hygro
- Gene Silencing Induced by siRNA Expression Plasmids
- Silencing of Gene Expression by PCR-based siRNA Expression Cassettes
- RNA-Protein Interactions and Translation Repression
- 2. RNAi Applications
- Growth Trends Global RNAi Application Market
- Exhibit 96: Global RNAi Market: Major Applications (Other,
Therapeutics, Research and Drug Development) Ranked by Projected CAGR for
2005 through 2012 (Graphical Representation Included)
- Research
- Growth Trends Global Market RNAi in Research
- Exhibit 97: Global RNAi Market in Research: Geographic Regions (Rest
of World, Asia-Pacific, United States, and Europe) Ranked by Projected
CAGR for 2005 through 2012 (Graphical Representation Included)
- Functional Genomics
- Metabolic Pathways
- Protein Chemistry
- Therapeutics
- Growth Trends Global Market for RNAi in Therapeutics
- Exhibit 98: Global Market for RNAi in Therapeutics: Geographic Regions
(Asia-Pacific, Rest of World, Europe, and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Therapeutic Approaches based on RNA
- Challenges for RNA based Drugs
- Delivery, the Most Urgent Objective
- Drug Development
- Growth Trends Global Market for RNAi in Drug Development
- Exhibit 99: Global Market for RNAi in Drug Development: Geographic
Regions (Asia-Pacific, Rest of World, Europe, and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- 3. RNAi Tools/Products
- Growth Trends Global RNAi Tools/Products
- Exhibit 100: Global Market for RNAi: Tools/Products
(Monitoring/Optimizing, Libraries, Synthesis, Delivery, Other, and
Design/Software) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Design/Software
- Growth Trends Global Market for RNAi Design/Software
- Exhibit 101: Global Market for Design/Software: Geographic Regions
(United States, Europe, Asia-Pacific and Rest of World) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- RNAi Mediated with siRNAs
- Synthesis
- Growth Trends Global Market for RNAi Synthesis
- Exhibit 102: Global Synthesis Market for RNAi : Geographic Regions
(Rest of World, Asia-Pacific, Europe, and United States) Ranked by
Projected CAGR - for 2005 through 2012 (Graphical Representation Included)
- Delivery
- Growth Trends Global Market for RNAi Delivery
- Exhibit 103: Global Market for RNAi DeliveryTools/Products :
Geographic Regions (Rest of World, Asia-Pacific, Europe, and United
States) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Key Techniques Used in Drug Delivery
- Electroporation
- Vector Based
- Transfection Reagents
- Monitoring/Optimizing
- Growth Trends Global Market for RNAi Monitoring/Optimizing
- Exhibit 104: Global Market for RNAi Monitoring/Optimizing: Geographic
Regions (Rest of World, Asia-Pacific, Europe, and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Control Experiments
- Establishing Gene Knockdown
- Libraries
- Growth Trends Global Market for RNAi Libraries
- Exhibit 105: Global Market for RNAi Libraries: Geographic Regions
(Asia-Pacific, Rest of World, Europe and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- Other
- Growth Trends Global Market for Other RNAi Tool/Products
- Exhibit 106: Global Market for Other RNAiTools/Products: Geographic
Regions (Asia-Pacific, Rest of World, Europe and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representation Included)
- 4. Product Trends
- Screening Assays
- RNAi and Nanoproteins
- Importance of Targeting Tumor Cells and Nanotechnology' s Contribution
- Application of RNAi in Drug Manufacture and Benefits Attributed to its
Use
- The Phenomenon of Gene Suppression or Gene Knockdown
- Various Applications of RNAi
- Application of RNAi Products as Potential Drug Candidates
- Use of RNAi Technology in Treatment of Various Blood Disorders
- Prominent Breakthrough in the Field of Cancer Research
- Use of RNAi in Healing Bacterial and Viral Disorders
- Application of RNAi in Treatment of HIV Cases
- Benefits Attributed to the Use of RNAi Technology In Hepatitis Disorders
- Application of RNAi in Treatment of Cardiovascular and Cerebral Vascular
Disorders
- Application of RNAi Technology in Healing Neurodegenerative Disorders
- miRNA Varieties: Antiproliferative and Proapoptotic
- Prevention of Malaria by Transformation of Mosquito by RNAi
- The Application of RNAi in the Treatment of Metabolism Related Disorders
- Gene Therapy for Sickle Cell Disease
- Application of RNAi in the Field of Medicine
- Some Potential Applications of RNAi to Human Diseases
- Hepatitis B Virus
- Respiratory Syncytial Virus
- Herpes Simplex Virus
- Neurodegenerative Diseases
- Cancers
- Clinical Trial Preparation
- The Vision and Future Prospects of The Research
- Achievements of RNAi Products
- Dark Areas and Hurdles in the Research
- Support of Major Pharmaceutical Companies-A key to Success
- Exhibit 107: Major Pharma Companies The RNAi Connection
- Advantages of RNAi Over Others
- RNAi in Research
- RNAi Revolutionizes Research
- An Array of Benefits
- In Vivo Gene Silencing
- Vitravene The Only Antisense Drug Approved
- RNAi - A Natural Alternative
- Antisense DNA or RNA
- Delivery, Delivery, Delivery
- Looking Ahead to the Clinic
- RNAi in Drug Discovery & Therapeutics
- Combining Tools and Technologies to Improve Delivery and Efficacy of
Key Compounds
- Delivery and Efficacy
- Lentiviral Delivery
- Reducing Off-target Effects
- Validating Knockdown
- MicroRNA Mimics
- RNAi Goes Genomic
- SPOT-RNAi Cell Arrays
- Methods for Incorporating RNAi in the Process of Drug Discovery
- Sequence Determination
- dsRNA Production
- Screening and Optimization
- Validation
- Delivery
- Sequence Design Parameters
- Design Parameters
- Filter Selection Criteria
- Parallel dsRNA Production
- RNAi and the Human Genome
- Experimentation in Ribonucleic Acid interference
- Built-in RNAi Machinery for the Development of Plants
- Post-Transcriptional Gene Silencing in Drosophila Cells Mediated by
RNA-Directed Nuclease
- Influence of Chromosome Organization and Chromatin Modification of
Genome Function and Evolution
- Effective Genetic Interference by Double Stranded RNA in Caenorhabditis
Elegans
- Structural Function for Double-Stranded RNA processing by Dicer
- The Role of Bidentate Ribonuclease in Initiating RNA Interference
- Cleavage of mRNA by Double-Stranded RNA at Intervals of 21 and 23
Nucleotides
- The Preferential Binding of Long Double-Stranded RNAs by RDE-4 and the
Subsequent Dimerization that is Essential for its Cleavage to siRNAs
- A New Link between the Initiation and Effector Stages of the RNAi
Pathway in Drosophila
- Two Separate Populations of Primary and Secondary Effectors are Present
During RNAi in Caenorhabditis Elegans
- Unprimed RNA Synthesis Result in Secondary siRNAs which then Form a
Discrete Class
- The Individual Roles of the Argonaute Proteins in Small RNA-Directed RNA
Cleavage Pathways
- The Role of Dicer-1 and Dicer-2 are different in the siRNA/miRNA
Silencing Pathways of Drosophila
- High-Throughput RNAi Screening In Vitro: From Cell Lines to Primary Cells
- The Advantages and Disadvantages of the Interference Process in Mammals
- Introduction to Nucleofection and Application of RNAi in Gene Silencing
- Effective Non-Viral Delivery
- Available Optimized Protocols
- 96-Well Shuttle
- The Impact of Non Reagent-based Transfection
- Various Problem Areas of RNAi
- RNA Interference: Problem Areas and Potential Applications for
Treatment of Human diseases
- Toxicities Owing to Competition with Cellular miRNAs
- Off-Target Effects Caused Due to Seed Sequence
- Triggering and Circumventing Interferon Responses
- Problems to be Overcome in Gene Therapy Involving RNAi
“Knock-down” Mice as In Vivo Model
- RNAi Enhances Drug Development
- RNAi Drug Candidates
- Benefits of RNAi-based Therapies
- Using the RNAi Process to Develop New Cancer Drugs
- The Role of RNA Interference in Treating Disorders of the Central
Nervous System
- Delivering on Promise of RNAi Therapeutics
- RNAi and Influenza
- The Future of RNA Interference
- Major Challenges Governing the Use of RNAi as a Therapy
- siRNA: Considered Future of In Vivo Mammalian Gene Research
- Critical Factors that Aid a Successful RNAi
- A Strong siRNA Design
- How to Choose a Model Cell System
- Combining Optimized Parameters Helps in the Discovery of New Drugs
IV. MARKET DYNAMICS
- 1. Market Overview
- RNAi A Breakthrough in Molecular Biology
- Global Market Analysis
- Exhibit 108: RNAi (2005-2012) - Global Market Analysis (Current &
Future) by Geographic Region for United States, Europe, Asia-Pacific and
Rest of World in US$ Million (Graphical Representation Included)
- Exhibit 109: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Global Market Value by Geographic Region for United States, Europe,
Asia-Pacific and Rest of World (Graphical Representation Included)
- Joint Venture Between Ambion and Cenix Bioscience Offers First Human
Genome-Wide siRNA Library
- 2. Market Trends
- RNAi An Emerging Class of Drugs in Pharmaceuticals
- Biotech/Pharma Industries' Interest in RNAi
- RNAi' s Functionality
- Sourcing and Market Potential
- Marketing Strategy
- Economic Possibilities
- The Mission Ahead for RNAi
- Biotech Companies Realize to Gain Billions of Dollars by Applying RNAi
Technology
- RNAi: Focus on Modeling Cellular Systems
- Introduction
- Initial Stages of Mammalian RNAi Screening
- Development of Signaling Pathways Using a Mammalian RNAi Screen
- Identification of Components in a Biological Process: RNA interference
- Component Discovery
- Reporter Assays and High-Content Image-based Screening
- Well-Based Arrayed Screening
- Pooled Screening
- Cell Microarrays
- Component Validation and Classification
- Classification
- Systems Analysis
- An Outlook on Binary Genetic Interactions with RNAi
- Hypothetical RNAi Screening for Cell-Growth Regulators
- Prospects of Knockdown Technology
- RNA interference (RNAi)
- Introduction
- Redefinition of RNA
- Knockdown of Genes
- RNAi on a Large Scale
- RNAi: Beyond Machinery
- Silencing Diseases
- Principle Behind RNAi
- Delivery
- Area of Concern
- 3. Major Companies in RNAi Industry
- Actigenics SA (France)
- Allele Biothechnology and Pharmaceuticals, Inc. (USA)
- alphaGEN Co. , Ltd.
- Alnylam Pharmaceuticals, Inc. (USA)
- Ambion, Inc. (USA)
- Antisense Therapeutics Limited (Australia)
- Applied Biosystems Group (USA)
- Asuragen, Inc. (USA)
- Avalon Pharmaceuticals, Inc. (USA)
- Benitec Ltd. (Australia)
- B-Bridge International, Inc.(USA)
- Clontech Laboratories, Inc. (USA)
- Calando Pharmaceuticals, Inc. (USA)
- Cenix Bioscience GmbH (Germany)
- CombiMatrix Corporation (USA)
- CytoPathfinder, Inc. (Japan)
- CytRx Corporation (USA)
- RXi Pharmaceuticals Corporation (USA)
- deVGen NV (Belgium)
- Dharmacon, Inc. (USA)
- Galenea Corporation (USA)
- Imgenex Corporation (USA)
- Intradigm Corporation (USA)
- Intronn, Inc. (USA)
- Invitrogen Corporation (USA)
- InvivoGen (USA)
- Lentigen Corporation (USA)
- Merck & Co. , Inc
- Mirus Bio Corporation (USA)
- Nastech Pharmaceutical Company, Inc. (USA)
- Nucleonics, Inc. (USA)
- Open Biosystems, Inc. (USA)
- Opko Health, Inc. (USA)
- Panomics, Inc. (USA)
- Promega Corporation (USA)
- Qiagen N. V.
- RNAx GmbH (Germany)
- SomaGenics, Inc. (USA)
- Santaris Pharma A/S (Denmark)
- Sigma-Aldrich Corporation (USA)
- Silence Therapeutics plc (UK)
- Targeted Genetics Corporation (USA)
- 4. Major Activities in RNAi Industry
- Nastech Pharmaceutical Allocates its RNA-based Intellectual Property to
its Subsidiary
- RXi Pharmaceuticals Acquires Exclusive Rights to RNAi Sequences to Genes
- Columbia University Medical Center and Rosetta Genomics in Development
Collaboration
- Asuragen Offers Newly Developed microRNA Services
- Invitrogen Corp. and RXi Pharmaceuticals in Collaboration Agreement for
Enhancement of RNAi Technology
- Exiqon' s Locked Nucleic Acids Licensed to Applied Biosystems
- New Series of siRNA Developed by Applied Biosystems
- Thermo Fisher Scientific and Lentigen Collaboration for Technology
Development
- Universite de Montreal to Study RNAi through Collaboration with
Sigma-Aldrich
- Isis and Alnylam Join Hands to Establish Regulus Therapeutics
- RNAi Center Funding in Massachusetts
- Silence Therapeutics Enters into Partnership with AstraZeneca
- RXi Pharma Signs License Agreement with Cold Spring Harbor Laboratory
- Two-Year Agreement between Mirus Bio and Pfizer for Evaluation of RNAi
Delivery Technology
- RXi Pharma Receives RNAi Assets from Parent Company
- Applied Biosystems Launches the StepOne Real-Time PCR System
- Nastech Acquires Exclusive Rights to RNAi Intellectual Property and
Technology
- Artemis Enters into Deal with Merck for Production of RNAi Mouse Models
- Senetek Enters into Agreement with Poland' s IBCPAS for Treating Brain
Tumors
- Merck Buys Entire Stake in Sirna Therapeutics
- Joint Effort to make a New Facility for Proteomics Profiling and Drug
Effects in Human Cells
- Framework Agreement signed between Cenix BioScience and Merck KGaA
- Invitrogen Launches Advanced Transfection Reagents
- Calando Picks Agilent for siRNA production
- Alnylam Receives Biodefense Contract worth US$ 23 million from
Government Agency
- Bio-Rad Enters into Alliance with Integrated DNA Technologies for
Developing RNAi
- Dharmacon Associates with Amaxa for Improved Delivery of siRNA into
Complex Cell Types
- QIAGEN Enters into Alliance with CytoPathfinder for Developing Novel
Equipment for High-Throughput RNAi Screening
- Sirna Signs an Agreement with GSK for Developing RNAi based Drugs for
Respiratory Disease Treatment
- Applied Biosystems Acquires Complete Stake in the Ambion' s Research
Products Division
- Nastech Acquires Galenea along with Galenea' s IP and Technology Rights
- Ambion Enters into Alliance with GE Healthcare for Reinforcing the study
on Micro-RNA Microarray
- Non-Exclusive License Agreement Signed Between Alnylam Pharma and
Eurogentec
- Ambion Furnishes Cepheid with Licenses of Armored RNA
- Ambion Extends Partnership with Wyeth for the Development and Supply of
RNA
- 5. Major Product Innovations/Launches in RNAi Industry
- Qiagen Launches RNA Purification Kit
- RXi Pharmaceuticals Granted Australian Patent Application License
- RXi Pharmaceuticals Signs License Agreement with TriLink Biotechnologies
for RNA Chemistry Technologies
- Sigma-Aldrich Introduces LentiExpress™ Technology for
High-Throughput RNAi Screening
- Rosetta Genomics is Issued a Second Patent for MicroRNAs
- Rosetta Genomics Signs Collaboration Agreement with Ben Gurion University
- US Government Signs $38 6 Million Contract with Alnylam
- Open Biosystems Launches New shRNAmir Library for RNA Interference
- Quark Pharmaceuticals Presents Positive Results in Pre-Clinical Studies
of Systemic RNAi Compound in ARF
- Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations
to Treat Neurodegenerative Diseases
- Oligo PRO™ 24HT System for the Parallel Analysis of
Oligonucleotide and RNAi Duplex Purity
- Mirus Bio Discovers New Breakthrough Technology for RNAi Therapeutics
- Kylin Therapeutics Signs License Agreement with Purdue University for
RNAi Delivery Technology
- Partnership Between Intradigm and Agilent to Develop RNA Interference
Oncology Therapeutic
- Alnylam Achieves Important Milestone in Collaborative Agreement
- Launch of New RNAi Services Laboratory to Continue Research in Drug
Discovery and Development
- Alnylam Initiates New Research Program on RNAi Therapeutics
- Alnylam Announces Advancement of New RNAi Therapeutic Development Program
- Alnylam Grants License to Bio-Rad for Kreutzer-Limmer Patents in the
RNAi Research Products Market
- Luminex and Exiqon Jointly Produce New microRNAs Product Line
- Mirus Bio Granted Broad RNAi Patent Using its Proprietary Hydrodynamic
Intravascular Injection
- Invitrogen Launches Advanced Transfection Reagents
- Exiqon Establishes Sales Headquarters in the US
- Mirus Bio Announces New Tool for Gene Function Analysis
- Alnylam Grants Quark License to Develop and Commercialize RNAi
Therapeutic Products
- Exiqon Signs License Agreement with Max Planck Society for Diagnostic
Use of Micro-RNAs
- Abbott and Dharmacon Collaborate to Develop siRNA-Based Therapeutics
- Acuity signs a pact with ZaBeCor for developing anti-inflammatory siRNA
- Invitrogen Signs Agreement with genOway
- Invitrogen Launches Stealth™ RNAi Human Kinase Collection
- Novartis joins hands with Alnylam for RNAi Therapeutics Innovation
- SB introduces Genome-Wide Human and Mouse siRNA Libraries
- Analysis by Application
- Exhibit 110: RNAi (2005-2012) - Global Market Analysis (Current &
Future) by Application Area for Research, Therapeutics, Drug Development,
and Other in US$ Million (Graphical Representation Included)
- Exhibit 111: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Global Market Value by Application Area for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 112: RNAi in Research (2005-2012) - Global Market Analysis
(Current & Future) - by Application for Functional Genomics, Protein
Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 113: RNAi in Research (2006, 2009 and 2012)- Percentage
Breakdown of Global Market Value by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 114: RNAi in Therapeutics (2005-2012) - Global Market Analysis
(Current and Future) by Application for Ophthalmology, Virology, Neurology,
Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 115: RNAi in Therapeutics (2006, 2009 and 2012)- Percentage
Breakdown of Global Market Value by Application for Ophthalmology, Virology,
Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 116: RNAi in Drug Development (2005-2012)- Global Market
Analysis (Current and Future) by bApplication for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 117: RNAi in Drug Development (2006, 2009 and 2012)- Percentage
Breakdown of Global Market Value by Application for Target Validation,
Target Identification, Drug Mechanism and Other (Graphical Representation Included)
- Analysis by Tools/Products
- Exhibit 118: RNAi (2005-2012) - Global Market Analysis (Current &
Future) by Tools/Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 119: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Global Market Value by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing , Libraries and Other (Graphical Representation Included)
- Tools/Products Analysis by Design/Software
- Exhibit 120: RNAi Design/Software Tools/Products (2005-2012) - Global
Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis
Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 121: RNAi Design/Software Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other (Graphical Representation Included)
- Tools/Products Analysis by Synthesis
- Exhibit 122: RNAi Synthesis Tools/Products (2005-2012)- Global Market
Analysis (Current and Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 123: RNAi Synthesis Tools/Products (2006, 2009 and
2012)-Percentage Breakdown of Global Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 124: RNAi Delivery Tools/Products (2005-2012) - Global Market
Analysis (Current & Future) for Vector Based, Transfection Reagents,
Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 125: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value for Vector Based, Transfection
Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 126: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Global Market Analysis (Current & Future) for Primers for RTqPCR, Controls,
miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 127: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Global Market Value for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other (Graphical Representation Included)
- Tools/Products Analysis by Libraries
- Exhibit 128: RNAi Libraries Tools/Products (2005-2012) - Global Market
Analysis (Current and Future) for Human, Mouse, Rat and Other in US$ Million
(Graphical Representation Included)
- Exhibit 129: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Global Market Value for Human, Mouse, Rat and Other
(Graphical Representation Included)
- 6. Regional Market Analysis
- A. The United States
- Market Analysis
- Exhibit 130: RNAi (2005-2012) - United States Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 131: List of Major Companies in the US
- Analysis by Application
- Exhibit 132: RNAi Applications (2005-2012) - United States Market
Analysis (Current and Future) for Research, Therapeutics, Drug Development
and Other in US$ Million (Graphical Representation Included)
- Exhibit 133: RNAi Applications (2006, 2009 and 2012) - Percentage
Breakdown of United States Market Value for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 134: RNAi in Research (2005-2012)- United States Market
Analysis (Current & Future) by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 135: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of United States Market Value by Application for Functional
Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 136: RNAi in Therapeutics (2005-2012)- United States Market
Analysis (Current & Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 137: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of United States Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 138: RNAi in Drug Development (2005-2012) - United States
Market Analysis (Current & Future) by Application for Target Validation,
Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 139: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of United States Market Value by Application for
Target Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 140: RNAi Tools/Products (2005-2012) - United States Market
Analysis (Current & Future) for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 141: RNAi Tools/Products (2006, 2009 and 2012) - Percentage
Breakdown of United States Market Value for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 142: RNAi Design/Software Tools/Products (2005-2012) -
United States Market Analysis (Current & Future) for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other in US$ Million
(Graphical Representation Included)
- Exhibit 143: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of United States Market Value for miRNA Target
Scan, miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 144: RNAi Synthesis Tools/Products (2005-2012) - United
States Market Analysis (Current & Future) for Expression Vectors,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$
Million (Graphical Representation Included)
- Exhibit 145: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of United States Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 146: RNAi Delivery Tools/Products (2005-2012) - United
States Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 147: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of United States Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 148: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
United States Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 149: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of United States Market Value for Primers
for RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 150: RNAi Libraries Tools/Products (2005-2012) - United
States Market Analysis (Current & Future) for Human, Mouse, Rat and Other
in US$ Million (Graphical Representation Included)
- Exhibit 151: RNAi Libraries Tools/Products (2006, 2009 and 2012)
Breakdown of United States Market Value for Human, Mouse, Rat and Other
(Graphical Representation Included)
- B. Europe
- Market Analysis
- Exhibit 152: RNAi (2005-2012) - European Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Exhibit 153: List of Major Companies in Europe
- Analysis by Application
- Exhibit 154: RNAi (2005-2012) - European Market Analysis (Current &
Future) by Application Area for Research, Therapeutics, Drug Development
and Other in US$ Million (Graphical Representation Included)
- Exhibit 155: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
European Market Value by Application Area for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 156: European Application Market Analysis (Current & Future)
by Research for Genetics, Metabolism, Protein Chemistry & Others in US$
Million (Graphical Representation Included)
- Exhibit 157: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of European Market Value by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 158: RNAi in Therapeutics (2005-2012) - European Market
Analysis (Current and Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 159: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of European Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other
- Application Analysis by Drug Development
- Exhibit 160: RNAi in Drug Development (2005 - 2012)- European Market
Analysis (Current & Future) for Target Validation, Target Identification,
Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 161: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value for Target Validation,
Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 162: RNAi (2005-2012) - European Market Analysis (Current &
Future) by Tools/Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 163: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
European Market Value by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing , Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 164: RNAi Design/Software Tools/Products (2005-2012) -
European Market Analysis (Current & Future) for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 165: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of European Market Value for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 166: RNAi Synthesis Tools/Products (2005-2012) - European
Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 167: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value for Expression Vector,
Chemical, miRNA isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 168: RNAi Delivery Tools/Products (2005-2012) - European
Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 169: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 170: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
European Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 171: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of European Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 172: RNAi Libraries Tools/Products (2005-2012) - European
Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$
Million (Graphical Representation Included)
- Exhibit 173: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of European Market Value for Human, Mouse, Rat and
Other (Graphical Representation Included)
- B1. Germany
- German Market Analysis
- Exhibit 174: RNAi (2005-2012) - German Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 175: RNAi (2005-2012) - German Market Analysis (Current &
Future) by Application for Research, Therapeutics, Drug Development and
Other in US$ Million (Graphical Representation Included)
- Exhibit 176: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
German Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 177: RNAi in Research (2005-2012) - German Market Analysis
(Current & Future) - by Application for Functional Genomics, Protein
Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 178: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of German Market Value by Appliation for Functional Genomics,
Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 179: RNAi in Therapeutics (2005-2012) - German Market Analysis
(Current and Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 180: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of German Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other
- Application Analysis by Drug Development
- Exhibit 181: RNAi in Drug Development (2005-2012)- German Market
Analysis (Current & Future) by Application for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 182: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of German Market Value by Application for Target
Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 183: RNAi (2005-2012) - German Market Analysis (Current &
Future) by Tools/Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 184: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
German Market Value by Tools/ Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other (Graphical Representation Included)
- Tools/Products Analysis by Design/Software
- Exhibit 185: RNAi Design/Software Tools/Products (2005-2012) - German
Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis
Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 186: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of German Market Value for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other (Graphical Representation Included)
- Tools/Products Analysis by Synthesis
- Exhibit 187: RNAi Synthesis Tools/Products (2005-2012) - German Market
Analysis (Current & Future) Synthesis for Expression Vector, Chemical,
miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million
(Graphical Representation Included)
- Exhibit 188: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of German Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 189: RNAi Delivery Tools/Products (2005-2012) - German Market
Analysis (Current & Future) for Vector Based, Transfection Reagents,
Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 190: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of German Market Value for Vector Based, Transfection
Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 191: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
German Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 192: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of German Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products by Libraries
- Exhibit 193: RNAi Libraries Tools/Products (2005-2012) - German Market
Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million
(Graphical Representation Included)
- Exhibit 194: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of German Market Value for Human, Mouse, Rat and
Other (Graphical Representation Included)
- B2. The United Kingdom
- UK Market Analysis
- Exhibit 195: RNAi (2005-2012) - United Kingdom Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 196: RNAi (2005-2012) - United Kingdom Market Analysis
(Current & Future) by Application for Research, Therapeutics, Drug
Development and Other in US$ Million (Graphical Representation Included)
- Exhibit 197: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
United Kingdom Market Value by Application for Research, Therapeutics,
Drug Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 198: RNAi in Research (2005-2012) - United Kingdom Market
Analysis (Current & Future) by Application for Functional Genomics,
Protein Chemistry Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 199: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of United Kingdom Market Value by Application for Functional
Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 200: RNAi in Therapeutics (2005-2012)- United Kingdom Market
Analysis (Current & Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 201: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of United Kingdom Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other
- Application Analysis by Drug Development
- Exhibit 202: RNAi in Drug Development (2005-2012) - United Kingdom
Market Analysis (Current & Future) by Application for Target Validation,
Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 203: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of United Kingdom Market Value by Application for
Target Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 204: RNAi (2005-2012) - United Kingdom Market Analysis
(Current & Future) by Tools/ Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million
(Graphical Representation Included)
- Exhibit 205: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
United Kingdom Market Value by Tools/Products for Design/Software,
Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other (Graphical Representation Included)
- Tools/Products Analysis by Design/Software
- Exhibit 206: RNAi Design/Software Tools/Products (2005-2012) - United
Kingdom Market Analysis (Current & Future) for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 207: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of United Kingdom Market Value for miRNA Target
Scan, miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 208: RNAi Synthesis Tools/Products (2005-2012) - United
Kingdom Market Analysis (Current & Future) for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$
Million (Graphical Representation Included)
- Exhibit 209: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of United Kingdom Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 210: RNAi Delivery Tools/Products (2005-2012) - United Kingdom
Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 211: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of United Kingdom Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 212: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
UK Market Analysis (Current & Future) for Primers for RTqPCR, Controls,
miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 213: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of United Kingdom Market Value for Primers
for RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 214: RNAi Libraries Tools/Products (2005-2012) - United
Kingdom Market Analysis (Current & Future) for Human, Mouse, Rat and Other
in US$ Million (Graphical Representation Included)
- Exhibit 215: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of United Kingdom Market Value for Human, Mouse, Rat
and Other (Graphical Representation Included)
- B3. Belgium
- Belgian Market Analysis
- Exhibit 216: RNAi (2005-2012) - Belgian Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 217: RNAi (2005-2012) - Belgian Market Analysis (Current &
Future) by Application for Research, Therapeutics, Drug Development and
Other in US$ Million (Graphical Representation Included)
- Exhibit 218: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Belgian Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 219: RNAi in Research (2005-2012) - Belgian Market Analysis
(Current and Future) by Application for Functional Genomics, Protein
Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 220: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Belgian Market Value by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 221: RNAi in Therapeutics (2005-2012) - Belgian Market
Analysis (Current and Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 222: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Belgian Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other
- Application Analysis by Drug Development
- Exhibit 223: RNAi in Drug Development (2005-2012) - Belgian Market
Analysis (Current & Future) by Application for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 224: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Belgian Market Value by Application for Target
Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 225: RNAi (2005-2012) - Belgian Market Analysis (Current &
Future) by Tools/Products for Design/Software, Synthesis, Delivery,
Monitoring/ Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 226: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Belgian Market Value by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 227: RNAi Design/Software Tools/Products (2005-2012) - Belgian
Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis
Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 228: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Belgian Market Value for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 229: RNAi Design/Software Tools/Products (2005-2012) - Belgian
Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/ RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 230: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Belgian Market Value Synthesis for Expression
Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 231: RNAi Delivery Tools/Products (2005-2012) - Belgian Market
Analysis (Current & Future) for Vector Based, Transfection Reagents,
Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 232: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Belgian Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 233: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Belgian Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 234: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Belgian Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 235: RNAi Libraries Tools/Products (2005-2012) Belgian Market
Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million
(Graphical Representation Included)
- Exhibit 236: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Belgian Market Value for Human, Mouse, Rat and
Other (Graphical Representation Included)
- B4. France
- French Market Analysis
- Exhibit 237: RNAi (2005-2012) - French Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 238: RNAi (2005-2012) - French Market Analysis (Current &
Future) by Application for Research, Therapeutics, Drug Development and
Other in US$ Million (Graphical Representation Included)
- Exhibit 239: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
French Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 240: RNAi in Research (2005-2012) - French Market Analysis
(Current & Future) by Application for Functional Genomics, Protein
Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 241: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of French Market Value by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 242: RNAi in Therapeutics (2005-2012) - French Market Analysis
(Current and Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 243: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of French Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other
- Application Analysis by Drug Development
- Exhibit 244: RNAi in Drug Development (2005-2012) - French Market
Analysis (Current & Future) - by Application for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 245: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of French Market Value by Application for Target
Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 246: RNAi (2005-2012) - French Market Analysis (Current &
Future) by Tools/Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 247: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
French Market Value by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 248: RNAi Design/Software Tools/Products (2005-2012) - French
Market Analysis (Current & Future) for miRNA Target Scan, miRNA Analysis
Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 249: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of French Market Value for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 250: RNAi Synthesis Tools/Products (2005-2012) - French Market
Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 251: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of French Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 252: RNAi Delivery Tools/Products (2005-2012) - French Market
Analysis (Current & Future) for Vector Based, Transfection Reagents,
Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 253: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of French Market Value for Vector Based, Transfection
Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 254: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
French Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 255: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of French Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 256: RNAi Libraries Tools/Products (2005-2012) - French Market
Analysis (Current & Future) for Human, Mouse, Rat and Other in US$ Million
(Graphical Representation Included)
- Exhibit 257: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of French Market Value for Human, Mouse, Rat and
Other (Graphical Representation Included)
- B5. Rest of Europe
- Rest of Europe Market Analysis
- Exhibit 258: RNAi (2005-2012) - Rest of Europe Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 259: RNAi (2005-2012) - Rest of Europe Market Analysis
(Current & Future) by Application for Research, Therapeutics, Drug
Development and Other in US$ Million (Graphical Representation Included)
- Exhibit 260: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Rest of Europe Market Value by Application for Research, Therapeutics,
Drug Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 261: RNAi in Research (2005-2012) - Rest of Europe Market
Analysis (Current & Future) by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 262: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Rest of Europe Market Value by Application for Functional
Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 263: RNAi in Therapeutics (2005-2012) - Rest of Europe Market
Analysis (Current & Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 264: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Rest of Europe Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other
- Application Analysis by Drug Development
- Exhibit 265: RNAi in Drug Development (2005-2012) - Rest of Europe
Market Analysis (Current & Future) for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 266: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Europe Market Value by Application for
Target Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 267: RNAi (2005-2012) - Rest of Europe Market Analysis
(Current & Future) by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million
(Graphical Representation Included)
- Exhibit 268: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Rest of Europe Market Value by Tools/Products for Design/Software,
Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 269: RNAi Design/Software Tools/Products (2005-2012) - Rest of
Europe Market Analysis (Current & Future) for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 270: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Rest of Europe Market Value for miRNA Target
Scan, miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 271: RNAi Synthesis Tools/Products (2005-2012) - Rest of
Europe Market Analysis (Current & Future) for Expression Vector, Chemical,
miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million
(Graphical Representation Included)
- Exhibit 272: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Europe Market Value for Expression
Vectors, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 273: RNAi Delivery Tools/Products (2005-2012) - Rest of Europe
Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 274: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Europe Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 275: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Rest of Europe Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 276: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Rest of Europe Market Value for Primers
for RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 277: RNAi Libraries Tools/Products (2005-2012) - Rest of
Europe Market Analysis (Current & Future) for Human, Mouse, Rat and Other
in US$ Million (Graphical Representation Included)
- Exhibit 278: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Europe Market Value for Human, Mouse, Rat
and Other (Graphical Representation Included)
- C. Asia-Pacific
- Asia-Pacific Market Analysis
- Exhibit 279: RNAi (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 280: List of Major Companies in Asia-Pacific
- Analysis by Application
- Exhibit 281: RNAi (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) by Application for Research, Therapeutics, Drug
Development and Other in US$ Million (Graphical Representation Included)
- Exhibit 282: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Asia-Pacific Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 283: RNAi in Research (2005-2012) - Asia-Pacific Market
Analysis (Current and Future) by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 284: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Asia-Pacific Market Value by Application for Functional
Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 285: RNAi in Therapeutics (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 286: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Asia-Pacific Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 287: RNAi in Drug Development (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) by Application for Target Validation,
Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 288: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value by Application for
Target Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 289: RNAi (2005-2012) - Asia-Pacific Market Analysis
(Current & Future) by Tools/ Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million
(Graphical Representation Included)
- Exhibit 290: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Asia-Pacific Market Value by Tools/Products for Design/Software,
Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 291: RNAi Design/Software Tools/Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other in US$ Million
(Graphical Representation Included)
- Exhibit 292: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Asia-Pacific Market Value for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 293: RNAi Synthesis Tools/Products (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 294: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other (Graphical Representation Included)
- Tools/Products Analysis by Delivery
- Exhibit 295: RNAi Delivery Tools/Products (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation, and Other in US$ Million (Graphical Representation Included)
- Exhibit 296: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 297: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 298: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Asia-Pacific Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 299: RNAi Libraries Tools/Products (2005-2012) - Asia-Pacific
Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$
Million (Graphical Representation Included)
- Exhibit 300: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Asia-Pacific Market Value for Human, Mouse, Rat
and Other (Graphical Representation Included)
- C1. Australia
- Australian Market Analysis
- Exhibit 301: RNAi (2005-2012) - Australian Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 302: RNAi (2005-2012) - Australian Market Analysis (Current &
Future) - by Application for Research, Therapeutics, Drug Development and
Other in US$ Million (Graphical Representation Included)
- Exhibit 303: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Australian Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 304: RNAi in Research (2005-2012) - Australian Market Analysis
(Current and Future) by Application for Functional Genomics, Protein
Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 305: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Australian Market Value by Application for Functional
Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 306: RNAi in Therapeutics (2005-2012) - Australian Market
Analysis (Current and Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 307: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Australian Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 308: RNAi in Drug Development (2005-2012) - Australian Market
Analysis (Current & Future) by Application for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 309: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Australian Market Value by Application for Target
Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 310: RNAi (2005-2012) - Australian Market Analysis (Current
& Future) by Tools/Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 311: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Australian Market Value by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 312: RNAi Design/Software Tools/Products (2005-2012) -
Australian Market Analysis (Current & Future) for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 313: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Australian Market Value for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 314: RNAi Synthesis Tools/Products (2005-2012) - Australian
Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 315: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Australian Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 316: RNAi Delivery Tools/Products (2005-2012) - Australian
Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 317: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Australian Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 318: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Australian Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 319: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Australian Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 320: RNAi Libraries Tools/Products (2005-2012) - Australian
Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$
Million (Graphical Representation Included)
- Exhibit 321: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Australian Market Value for Human, Mouse, Rat and
Other (Graphical Representation Included)
- C2. Japan
- Japanese Market Analysis
- Exhibit 322: RNAi (2005-2012) - Japanese Market Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 323: RNAi (2005-2012) - Japanese Market Analysis (Current &
Future) by Application for Research, Therapeutics, Drug Development and
Other in US$ Million (Graphical Representation Included)
- Exhibit 324: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Japanese Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 325: RNAi in Research (2005-2012) - Japanese Market Analysis
(Current and Future) by Application for Functional Genomics, Protein
Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 326: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Japanese Market Value by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 327: RNAi in Therapeutics (2005-2012) - Japanese Market
Analysis (Current and Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 328: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Japanese Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 329: RNAi in Drug Development (2005-2012) - Japanese Market
Analysis (Current & Future) by Application for Target Validation, Target
Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 330: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Japanese Market Value by Application for Target
Validation, Target Identification, Drug Mechanism and Other (Graphical Representation Included)
- Analysis by Tools/Products
- Exhibit 331: RNAi (2005-2012) - Japanese Market Analysis (Current &
Future) by Tools/ Products for Design/Software, Synthesis, Delivery,
Monitoring/Optimizing, Libraries and Other in US$ Million (Graphical Representation Included)
- Exhibit 332: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Japanese Market Value by Tools/ Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing , Libraries and Other (Graphical Representation Included)
- Tools/Products Analysis by Design/Software
- Exhibit 333: RNAi Design/Software Tools/Products (2005-2012) -
Japanese Market Analysis (Current & Future) for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 334: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Japanese Market Value for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 335: RNAi Synthesis Tools/Products (2005-2012) - Japanese
Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 336: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Japanese Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 337: RNAi Delivery Design/Software Tools/Products (2005-2012)
- Japanese Market Analysis (Current & Future) for Vector Based,
Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 338: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Japanese Market Value for Vector Based,
Transfection Reagents, Electroporation and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 339: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Japanese Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 340: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Japanese Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 341: RNAi Libraries Tools/Products (2005-2012) - Japanese
Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$
Million (Graphical Representation Included)
- Exhibit 342: RNAi LibrariesTools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Japanese Market Value for Human, Mouse, Rat and
Other (Graphical Representation Included)
- C3. Rest of Asia-Pacific
- Exhibit 343: RNAi (2005-2012) - Rest of Asia-Pacific Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 344: RNAi (2005-2012) - Rest of Asia-Pacific Market Analysis
(Current & Future) by Application for Research, Therapeutics, Drug
Development and Other in US$ Million (Graphical Representation Included)
- Exhibit 345: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Rest of Asia-Pacific Market Value by Application for Research,
Therapeutics, Drug Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 346: RNAi in Research (2005-2012) - Rest of Asia-Pacific
Market Analysis (Current & Future) by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 347: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Rest of Asia-Pacific Market Value by Application for
Functional Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 348: RNAi in Therapeutics (2005-2012) - Rest of Asia-Pacific
Market Analysis (Current & Future) by Application for Ophthalmology,
Virology, Neurology, Oncology and Other in US$ Million (Graphical Representation Included)
- Exhibit 349: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Rest of Asia-Pacific Application Market Value by Application
for Ophthalmology, Virology, Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 350: RNAi in Drug Development (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) by Application for Target
Validation, Target Identification, Drug Mechanism and Other in US$ Million
(Graphical Representation Included)
- Exhibit 351: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Asia-Pacific Market Value by Application
for Target Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 352: RNAi (2005-2012) - Rest of Asia-Pacific Market Analysis
(Current & Future) by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million
(Graphical Representation Included)
- Exhibit 353: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Rest of Asia-Pacific Market Value by Tools/Products for Design/Software,
Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other
- Tools/Products Analysis by Design/Software
- Exhibit 354: RNAi Design/Software Tools/Products (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) for miRNA Target Scan,
miRNA Analysis Software, Design Algorithm and Other in US$ Million
(Graphical Representation Included)
- Exhibit 355: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Rest of Asia-Pacific Market Value for miRNA
Target Scan, miRNA Analysis Software, Design Algorithm and Other
- Tools/Products Analysis by Synthesis
- Exhibit 356: RNAi Synthesis Tools/Products (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other in US$
Million (Graphical Representation Included)
- Exhibit 357: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Asia-Pacific Market Value for Expression
Vector, Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 358: RNAi Delivery Tools/Products (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) for Vector Based,
Transfection Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 359: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Asia-Pacific Market Value for Vector
Based, Transfection Reagents, Electroporation and Other (Graphical Representation Included)
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 360: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Rest of Asia-Pacific Market Analysis (Current & Future) for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other in US$ Million
(Graphical Representation Included)
- Exhibit 361: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Rest of Asia-Pacific Market Value for
Primers for RTqPCR, Controls, miRNA Detection Tools and Other
- Tools/Products Analysis by Libraries
- Exhibit 362: RNAi Libraries Tools/Products (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) for Human, Mouse, Rat and
Other in US$ Million (Graphical Representation Included)
- Exhibit 363: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of Asia-Pacific Market Value for Human,
Mouse, Rat and Other (Graphical Representation Included)
- D. Rest of World
- Rest of World Market Analysis
- Exhibit 364: RNAi (2005-2012) - Rest of World Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Analysis by Application
- Exhibit 365: RNAi (2005-2012) - Rest of World Market Analysis
(Current & Future) by Application for Research, Therapeutics, Drug
Development and Other in US$ Million (Graphical Representation Included)
- Exhibit 366: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Rest of World Market Value by Application for Research, Therapeutics, Drug
Development and Other (Graphical Representation Included)
- Application Analysis by Research
- Exhibit 367: RNAi in Research (2005-2012) - Rest of World Market
Analysis (Current and Future) by Application for Functional Genomics,
Protein Chemistry, Metabolism and Other in US$ Million (Graphical Representation Included)
- Exhibit 368: RNAi in Research (2006, 2009 and 2012) - Percentage
Breakdown of Rest of World Market Value by Application for Functional
Genomics, Protein Chemistry, Metabolism and Other
- Application Analysis by Therapeutics
- Exhibit 369: RNAi in Therapeutics (2005-2012) - Rest of World Market
Analysis (Current & Future) by Application for Ophthalmology, Virology,
Neurology, Oncology and Other in US$ Million (Graphical Representation
Included)
- Exhibit 370: RNAi in Therapeutics (2006, 2009 and 2012) - Percentage
Breakdown of Rest of World Market Value by Application for Ophthalmology,
Virology, Neurology, Oncology and Other (Graphical Representation Included)
- Application Analysis by Drug Development
- Exhibit 371: RNAi in Drug Development (2005-2012) - Rest of World
Market Analysis (Current & Future) by Application for Target Validation,
Target Identification, Drug Mechanism and Other in US$ Million (Graphical Representation Included)
- Exhibit 372: RNAi in Drug Development (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value by Application for
Target Validation, Target Identification, Drug Mechanism and Other
- Analysis by Tools/Products
- Exhibit 373: RNAi (2005-2012) - Rest of World Market Analysis
(Current & Future) by Tools/Products for Design/Software, Synthesis,
Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million
(Graphical Representation Included)
- Exhibit 374: RNAi (2006, 2009 and 2012) - Percentage Breakdown of
Rest of World Market Value by Tools/Products for Design/Software,
Synthesis, Delivery, Monitoring/Optimizing Libraries and Other (Graphical Representation Included)
- Tools/Products Analysis by Design/Software
- Exhibit 375: RNAi Design/Software Tools/Products (2005-2012) - Rest of
World Market Analysis (Current & Future) for miRNA Target Scan, miRNA
Analysis Software, Design Algorithm and Other in US$ Million (Graphical Representation Included)
- Exhibit 376: RNAi Design/Software Tools/Products (2006, 2009 and 2012)
- Percentage Breakdown of Rest of World Market Value for miRNA Target
Scan, miRNA Analysis Software, Design Algorithm and Other (Graphical Representation Included)
- Tools/Products Analysis by Synthesis
- Exhibit 377: RNAi Synthesis Tools/Products (2005-2012) - Rest of World
Market Analysis (Current & Future) for Expression Vector, Chemical, miRNA
Isolation, Dicer/RNAseIII, In Vitro and Other in US$ Million (Graphical Representation Included)
- Exhibit 378: RNAi Synthesis Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value for Expression Vector,
Chemical, miRNA Isolation, Dicer/RNAseIII, In Vitro and Other
- Tools/Products Analysis by Delivery
- Exhibit 379: RNAi Delivery Tools/Products (2005-2012) - Rest of World
Market Analysis (Current & Future) for Vector Based, Transfection
Reagents, Electroporation and Other in US$ Million (Graphical Representation Included)
- Exhibit 380: RNAi Delivery Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value for Vector Based,
Transfection Reagents, Electroporation, and Other
- Tools/Products Analysis by Monitoring/Optimizing
- Exhibit 381: RNAi Monitoring/Optimizing Tools/Products (2005-2012) -
Rest of World Market Analysis (Current & Future) for Primers for RTqPCR,
Controls, miRNA Detection Tools and Other in US$ Million (Graphical Representation Included)
- Exhibit 382: RNAi Monitoring/Optimizing Tools/Products (2006, 2009 and
2012) - Percentage Breakdown of Rest of World Market Value for Primers for
RTqPCR, Controls, miRNA Detection Tools and Other Tools/Products Analysis
by Libraries
- Exhibit 383: RNAi Libraries Tools/Products (2005-2012) - Rest of World
Market Analysis (Current & Future) for Human, Mouse, Rat and Other in US$
Million (Graphical Representation Included)
- Exhibit 384: RNAi Libraries Tools/Products (2006, 2009 and 2012) -
Percentage Breakdown of Rest of World Market Value for Human, Mouse, Rat
and Other (Graphical Representation Included)
- 7. RNAi - The Industry Outlook
V. CORPORATE DIRECTORY
|
|
|
|
| | |
View Cart
